Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 9/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421364 | 0.85 | EGLN2 (0.36) | EGLN2MAPK14TGFBR1ALDH1A1CYP1A2 | |
| SCHEMBL6415985 | 0.81 | ACACB (0.37) | EGLN2CYP1A2 | |
| SCHEMBL5913917 | 0.79 | CLK4 (0.43) | MAPK14USP2ALDH1A1CYP1A2MAPK1 | |
| SCHEMBL5913924 | 0.79 | CLK4 (0.43) | MAPK14USP2ALDH1A1CYP1A2MAPK1 | |
| SCHEMBL6417723 | 0.78 | CFD (0.34) | MAPK14MAPK1 | |
| SCHEMBL5310133 | 0.78 | EPHB4 (0.38) | MAPK14ACP1 | |
| SCHEMBL6415740 | 0.72 | KDR (0.33) | MAPK14CYP2C19 | |
| SCHEMBL5259529 | 0.72 | ACACB (0.36) | MAPK14CYP1A2 | |
| SCHEMBL5309889 | 0.72 | KDM4E (0.41) | EGLN2ALDH1A1MAPK1 | |
| SCHEMBL5914418 | 0.70 | MAPK14 (0.40) | MAPK14USP2ALDH1A1CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288502-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, IAPP, MAPT | EGLN2 4721/4885MAPK14 2261/4885TGFBR1 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.